Ofran® tablet: Each tablet contains Ondansetron 8mg as Ondansetron Hydrochloride Dihydrate BP.
Ofran® oral solution: Each 5ml solution contains Ondansetron 4mg as Ondansetron Hydrochloride Dihydrate BP.
Ofran® Injection: Each 4 ml solution contains Ondansetron 8 mg as Ondansetron Hydrochloride Dihydrate USP.
Ofran® (Ondansetron) is a selective 5HT₃ receptor antagonist. While its mechanism of action has not been fully characterized, Ofran® (Ondansetron) is not a dopamine-receptor antagonist. Ofran® (Ondansetron) is well absorbed from the gastrointestinal tract and undergoes some first-pass metabolism.
Ofran® is indicated for:
Prevention of chemotherapy induced nausea & vomiting (CINV):
In patients treated with potent inducers of CYP3A4 (i.e Phenytoin, Carbamazepine or Rifampicin), the clearance of Ondansetron was increased and Ondansetron blood concentrations were decreased. Data from small studies indicate that Ondansetron may reduce the analgesic effect of tramadol.
In pregnancy*: Pregnancy category B. Reproduction studies at daily oral dose up to 10 and 30mg/kg/day have been performed in animals and have revealed no evidence of impaired fertility harm to the fetus due to Ondansetron. There are, however, no adequate and well-controlled studies in pregnant women. So the drug should be used in pregnancy only if clearly needed.
In lactation*: Ondansetron excretes in milk of lactating animals. Caution should be exercised when Ondansetron is administered to nursing mother.
Store below 30° C. Protect from light. Keep all the medicines out of the reach of the children.